Po-Hong Liu

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/576910/publications.pdf

Version: 2024-02-01

98 papers 2,293 citations

279798 23 h-index 243625 44 g-index

100 all docs

100 docs citations

100 times ranked

3344 citing authors

#	Article	IF	CITATIONS
1	Clinical Utility of Albumin Bilirubin Grade as a Prognostic Marker in Patients with Hepatocellular Carcinoma Undergoing Transarterial Chemoembolization: a Systematic Review and Meta-analysis. Journal of Gastrointestinal Cancer, 2023, 54, 420-432.	1.3	8
2	No Increase in Colorectal Cancer Screening in 2019 After American Cancer Society Recommends Starting Screening atÂAge 45. Clinical Gastroenterology and Hepatology, 2023, 21, 1947-1949.e2.	4.4	4
3	Cryptogenic hepatocellular carcinoma: characteristics, outcome, and prognostic role of albumin-bilirubin (ALBI) grade vs easy ALBI grade. Scandinavian Journal of Gastroenterology, 2023, 58, 61-69.	1.5	4
4	Frequency of Bowel Movements and Risk of Diverticulitis. Clinical Gastroenterology and Hepatology, 2022, 20, 325-333.e5.	4.4	7
5	A New Tumor Burden Score and Albumin–Bilirubin Grade-Based Prognostic Model for Hepatocellular Carcinoma. Cancers, 2022, 14, 649.	3.7	17
6	Dual hepatitis B and C-associated hepatocellular carcinoma: clinical characteristics, outcome, and prognostic role of albumin–bilirubin grade. International Journal of Clinical Oncology, 2022, 27, 739-748.	2.2	5
7	Persistent Disparities in Colorectal Cancer Screening: A Tell-Tale Sign for Implementing New Guidelines in Younger Adults. Cancer Epidemiology Biomarkers and Prevention, 2022, 31, 1701-1709.	2.5	10
8	Albumin–Bilirubin (ALBI) Grade-Based Nomogram for Patients with Hepatocellular Carcinoma Undergoing Transarterial Chemoembolization. Digestive Diseases and Sciences, 2021, 66, 1730-1738.	2.3	10
9	Letter to the Editor: Using Circulating Biomarkers to Stage HCC: Pitfalls and Limitations. Hepatology, 2021, 73, 2611-2611.	7.3	0
10	Changing faces of hepatocellular carcinoma: East vs West. Liver International, 2021, 41, 1430-1431.	3.9	3
11	History of Diverticulitis and Risk of Incident Cardiovascular Disease in Men: A Cohort Study. Digestive Diseases and Sciences, 2021, , 1.	2.3	7
12	Changing patterns of etiology and management of hepatocellular carcinoma: need for global reappraisal. Journal of Gastroenterology, 2021, 56, 406-407.	5.1	1
13	ALBI grade in dialysis patients with hepatocellular carcinoma: prognostic impact and staging strategy. Journal of Gastrointestinal Oncology, 2021, 12, 722-734.	1.4	1
14	Hepatocellular Carcinoma Screening Process Failures in Patients with Cirrhosis. Hepatology Communications, 2021, 5, 1481-1489.	4.3	28
15	Easy albumin–bilirubin score as a new prognostic predictor in hepatocellular carcinoma. Hepatology Research, 2021, 51, 1129-1138.	3.4	17
16	Tumor burden score as a new prognostic marker for patients with hepatocellular carcinoma undergoing transarterial chemoembolization. Journal of Gastroenterology and Hepatology (Australia), 2021, 36, 3196-3203.	2.8	21
17	Selecting an optimal prognostic model for advanced hepatocellular carcinoma: Any new ideas?. Digestive and Liver Disease, 2021, 53, 1208-1209.	0.9	1
18	Predicting microvascular invasion in HCC with ctDNA: What are the pitfalls?. Liver International, 2021, 41, 1148-1149.	3.9	2

#	Article	IF	Citations
19	Comment on "Effect of Microvascular Invasion Risk on Early Recurrence of Hepatocellular Carcinoma After Surgery and Radiofrequency Ablation― Annals of Surgery, 2021, 274, e101-e102.	4.2	O
20	Albuminâ€bilirubin gradeâ€based nomogram of the BCLC system for personalized prognostic prediction in hepatocellular carcinoma. Liver International, 2020, 40, 205-214.	3.9	28
21	A New Prognostic Model Based on Albumin–Bilirubin Grade for Hepatocellular Carcinoma Beyond the Milan Criteria. Digestive Diseases and Sciences, 2020, 65, 658-667.	2.3	14
22	Association Between Inflammatory Diets, Circulating Markers of Inflammation, and Risk of Diverticulitis. Clinical Gastroenterology and Hepatology, 2020, 18, 2279-2286.e3.	4.4	19
23	Too Many versus Too Few Platelets in Patients with Hepatocellular Carcinoma: Good or Bad?. Liver Cancer, 2020, 9, 108-109.	7.7	1
24	Are inflammationâ€based models feasible tools in predicting the outcome of patients with hepatocellular carcinoma?. Liver International, 2020, 40, 1498-1498.	3.9	2
25	Development of a Novel Inflammation-Based Index for Hepatocellular Carcinoma. Liver Cancer, 2020, 9, 167-181.	7.7	28
26	Weight gain during early adulthood, trajectory of body shape and the risk of nonalcoholic fatty liver disease: A prospective cohort study among women. Metabolism: Clinical and Experimental, 2020, 113, 154398.	3.4	7
27	Fruit and vegetable consumption is associated with lower prevalence of asymptomatic diverticulosis: a cross-sectional colonoscopy-based study. BMC Gastroenterology, 2020, 20, 221.	2.0	4
28	Tumour burden score for hepatocellular carcinoma: Is it an authentic prognostic marker?. British Journal of Surgery, 2020, 107, e625-e625.	0.3	0
29	Metavir Fibrosis Stage in Hepatitis C–Related Hepatocellular Carcinoma and Association with Noninvasive Liver Reserve Models. Journal of Gastrointestinal Surgery, 2020, 24, 1860-1862.	1.7	1
30	Survival of Patients with Hepatocellular Carcinoma in Renal Insufficiency: Prognostic Role of Albumin-Bilirubin Grade. Cancers, 2020, 12, 1130.	3.7	10
31	Treating Small Hepatocellular Carcinoma: Stereotactic Body Radiation Therapy Versus Radiofrequency Ablation. Journal of Gastroenterology and Hepatology (Australia), 2020, 35, 2020-2020.	2.8	1
32	Thrombocytosis is associated with worse survival in patients with hepatocellular carcinoma. Liver International, 2020, 40, 2522-2534.	3.9	20
33	Nomogram to predict surgical hepatocellular carcinoma with Child-Pugh B: Feasibility and overlooked predictors. Journal of Hepatology, 2020, 72, 1032-1033.	3.7	2
34	Evolution of etiology, presentation, management and prognostic tool in hepatocellular carcinoma. Scientific Reports, 2020, 10, 3925.	3.3	18
35	Differential Survival Impact of Diabetes Mellitus on Hepatocellular Carcinoma: Role of Staging Determinants. Digestive Diseases and Sciences, 2020, 65, 3389-3402.	2.3	2
36	Predicting post-resection recurrence of hepatocellular carcinoma: Spleen stiffness vs. ALBI grade. Journal of Hepatology, 2019, 70, 808.	3.7	1

#	Article	IF	Citations
37	Becoming a Statistic in the Middle of an Epidemicâ€"A Call to Consider Alternate Risk Factors for Early-Onset Colorectal Cancerâ€"In Reply. JAMA Oncology, 2019, 5, 1228.	7.1	O
38	Obesity and Weight Gain Since Early Adulthood Are Associated With a Lower Risk of Microscopic Colitis. Clinical Gastroenterology and Hepatology, 2019, 17, 2523-2532.e1.	4.4	19
39	Menopausal Hormone Therapy and Risk of Diverticulitis. American Journal of Gastroenterology, 2019, 114, 315-321.	0.4	14
40	Intake of Dietary Fiber, Fruits, and Vegetables and Risk of Diverticulitis. American Journal of Gastroenterology, 2019, 114, 1531-1538.	0.4	38
41	An Albumin-Bilirubin (ALBI) Grade–based Prognostic Model For Patients With Hepatocellular Carcinoma Within Milan Criteria. American Journal of Clinical Oncology: Cancer Clinical Trials, 2019, 42, 698-704.	1.3	15
42	Dietary Gluten Intake and Risk of Microscopic Colitis Among US Women without Celiac Disease: A Prospective Cohort Study. American Journal of Gastroenterology, 2019, 114, 127-134.	0.4	12
43	Albumin-bilirubin (ALBI) grade-based nomogram to predict tumor recurrence in patients with hepatocellular carcinoma. European Journal of Surgical Oncology, 2019, 45, 776-781.	1.0	38
44	Staging and Restaging for Hepatocellular Carcinoma: Solution of Confusion?. Hepatology, 2019, 69, 464-465.	7.3	0
45	Association of Obesity With Risk of Early-Onset Colorectal Cancer Among Women. JAMA Oncology, 2019, 5, 37.	7.1	305
46	Magic mirror on the wall: Which is the best biomarker for hepatocellular carcinoma?. Hepatology, 2018, 67, 2482-2483.	7.3	3
47	Association Between Obesity and Weight Change and Risk of Diverticulitis in Women. Gastroenterology, 2018, 155, 58-66.e4.	1.3	46
48	Metastasis in patients with hepatocellular carcinoma: Prevalence, determinants, prognostic impact and ability to improve the Barcelona Clinic Liver Cancer system. Liver International, 2018, 38, 1803-1811.	3.9	18
49	Prognostic Performance of Ten Liver Function Models in Patients with Hepatocellular Carcinoma Undergoing Radiofrequency Ablation. Scientific Reports, 2018, 8, 843.	3.3	25
50	Detecting microvascular invasion in HCC with contrast-enhanced MRI: Is it a good idea?. Journal of Hepatology, 2018, 68, 862-863.	3.7	2
51	Using nomogram of the Barcelona Clinic Liver Cancer system for treatment selection in patients with stage C hepatocellular carcinoma. BMC Cancer, 2018, 18, 289.	2.6	19
52	Comparison of twelve liver functional reserve models for outcome prediction in patients with hepatocellular carcinoma undergoing surgical resection. Scientific Reports, 2018, 8, 4773.	3.3	26
53	Sedentary Behaviors, TV Viewing Time, and Risk of Young-Onset Colorectal Cancer. JNCI Cancer Spectrum, 2018, 2, pky073.	2.9	110
54	Identification of Menopausal and Reproductive Risk Factors for Microscopic Colitis—Results From the Nurses' Health Study. Gastroenterology, 2018, 155, 1764-1775.e2.	1.3	24

#	Article	IF	Citations
55	Current noninvasive liver reserve models do not predict histological fibrosis severity in hepatocellular carcinoma. Scientific Reports, 2018, 8, 15074.	3.3	8
56	Meta-Analysis of Bleeding Risk Prediction Scores in Patients After Percutaneous Coronary Intervention on Dual Antiplatelet Therapy. American Journal of Cardiology, 2018, 122, 1843-1852.	1.6	11
57	Hepatocellular Carcinoma with Portal Vein Tumor Involvement: Best Management Strategies. Seminars in Liver Disease, 2018, 38, 242-251.	3.6	95
58	Sa1070 - Obesity, Weight Change and Risk of Diverticulitis: A Prospective Cohort Study in Women. Gastroenterology, 2018, 154, S-229.	1.3	1
59	Ablation for Hepatocellular Carcinoma. Annals of Surgery, 2017, 266, e55-e56.	4.2	0
60	Treating Very Early-stage HCC. Annals of Surgery, 2017, 266, e31-e32.	4.2	2
61	A New Treatment-integrated Prognostic Nomogram of the Barcelona Clinic Liver Cancer System for Hepatocellular Carcinoma. Scientific Reports, 2017, 7, 7914.	3.3	6
62	Sepsis and Congestive Heart Failure as Strong Independent Factors in Elevated Troponin I. Journal of Cardiac Failure, 2017, 23, S34.	1.7	0
63	Comment on â€~Transarterial chemo-embolisation of hepatocellular carcinoma: impact of liver function and vascular invasion'. British Journal of Cancer, 2017, 117, e5-e5.	6.4	2
64	Retrospective cause analysis of troponin I elevation in non-CAD patients. Medicine (United States), 2017, 96, e8027.	1.0	5
65	Adherence to a Healthy Lifestyle Reduces Risk of Diverticulitis Among Men. Gastroenterology, 2017, 152, S943.	1.3	0
66	Performance status in patients with HCC: New kid on the block. Journal of Hepatology, 2017, 67, 1352-1353.	3.7	3
67	ALBI Score as a Novel Tool in Staging and Treatment Planning for Hepatocellular Carcinoma: Is It Sufficient. Liver Cancer, 2017, 6, 375-376.	7.7	2
68	Adherence to a Healthy Lifestyle is Associated With a Lower Risk of Diverticulitis among Men. American Journal of Gastroenterology, 2017, 112, 1868-1876.	0.4	63
69	Evaluation of the current guidelines for resection of hepatocellular carcinoma using the Appraisal of Guidelines for Research and Evaluation II instrument. Journal of Hepatology, 2017, 67, 991-998.	3.7	26
70	ALBI and PALBI grade predict survival for HCC across treatment modalities and BCLC stages in the MELD Era. Journal of Gastroenterology and Hepatology (Australia), 2017, 32, 879-886.	2.8	126
71	Prognostic impact of diabetes mellitus on hepatocellular carcinoma: Special emphasis from the BCLC perspective. PLoS ONE, 2017, 12, e0174333.	2.5	14
72	Prognostic role of noninvasive liver reserve markers in patients with hepatocellular carcinoma undergoing transarterial chemoembolization. PLoS ONE, 2017, 12, e0180408.	2.5	31

#	Article	IF	Citations
73	Impact of tumor burden on prognostic prediction for patients with terminal stage hepatocellular carcinoma: A nomogram study. PLoS ONE, 2017, 12, e0188031.	2.5	14
74	Surgical Resection Versus Radiofrequency Ablation for Single Hepatocellular Carcinoma â‰⊉ cm in a Propensity Score Model. Annals of Surgery, 2016, 263, 538-545.	4.2	148
75	Utility of prognostic scoring systems in management of hepatocellular carcinoma. European Journal of Cancer, 2016, 68, 206-207.	2.8	1
76	Proposal and validation of a new model to estimate survival for hepatocellular carcinoma patients. European Journal of Cancer, 2016, 63, 25-33.	2.8	40
77	Nomogram of the Barcelona Clinic Liver Cancer system for individual prognostic prediction in hepatocellular carcinoma. Liver International, 2016, 36, 1498-1506.	3.9	25
78	Reply to "Hepatocellular carcinoma scoring and staging systems. Do we need new tools?― Journal of Hepatology, 2016, 64, 1450-1452.	3.7	3
79	Prognosis of hepatocellular carcinoma: Assessment of eleven staging systems. Journal of Hepatology, 2016, 64, 601-608.	3.7	220
80	Surgical Resection is Better than Transarterial Chemoembolization for Patients with Hepatocellular Carcinoma Beyond the Milan Criteria: A Prognostic Nomogram Study. Annals of Surgical Oncology, 2016, 23, 994-1002.	1.5	38
81	Solitary Large Hepatocellular Carcinoma: Staging and Treatment Strategy. PLoS ONE, 2016, 11, e0155588.	2.5	37
82	Hepatocellular Carcinoma Patients With Performance Status 1 Deserve New Classification and Treatment Algorithm in the BCLC System. Medicine (United States), 2015, 94, e1223.	1.0	11
83	When to Perform Surgical Resection or Radiofrequency Ablation for Early Hepatocellular Carcinoma?. Medicine (United States), 2015, 94, e1808.	1.0	26
84	Impact of renal insufficiency on patients with hepatocellular carcinoma undergoing radiofrequency ablation. Journal of Gastroenterology and Hepatology (Australia), 2015, 30, 192-198.	2.8	4
85	Surgery for advanced hepatocellular carcinoma: Time to take action. Journal of Surgical Oncology, 2015, 112, 909-909.	1.7	0
86	Active Treatments Prolong the Survival in Patients With Hepatocellular Carcinoma and Performance Status 3 or 4. Journal of Clinical Gastroenterology, 2015, 49, 878-884.	2.2	3
87	Hong Kong Liver Cancer Staging System Is Associated With Better Performance for Hepatocellular Carcinoma. Medicine (United States), 2015, 94, e1772.	1.0	21
88	Aggressive Therapeutic Strategies Improve the Survival of Hepatocellular Carcinoma Patients with Performance Status 1 or 2: A Propensity Score Analysis. Annals of Surgical Oncology, 2015, 22, 1324-1331.	1.5	18
89	Surgical resection <i>versus</i> transarterial chemoembolization for BCLC stage C hepatocellular carcinoma. Journal of Surgical Oncology, 2015, 111, 404-409.	1.7	25
90	Radiofrequency Ablation is Better Than Surgical Resection in Patients With Hepatocellular Carcinoma Within the Milan Criteria and Preserved Liver Function. Journal of Clinical Gastroenterology, 2015, 49, 242-249.	2.2	33

#	Article	IF	CITATION
91	Inadvertent submucosal esophageal tunnel complicating ERCP. Endoscopy, 2015, 47, E289-E290.	1.8	2
92	Using Serum \hat{l} ±-Fetoprotein for Prognostic Prediction in Patients with Hepatocellular Carcinoma: What is the Most Optimal Cutoff?. PLoS ONE, 2015, 10, e0118825.	2.5	36
93	A New Child-Turcotte-Pugh Class 0 for Patients with Hepatocellular Carcinoma: Determinants, Prognostic Impact and Ability to Improve the Current Staging Systems. PLoS ONE, 2014, 9, e99115.	2.5	8
94	Uncompromised Treatment Efficacy in Elderly Patients With Hepatocellular Carcinoma. Medicine (United States), 2014, 93, e264.	1.0	20
95	Surgical Resection Versus Transarterial Chemoembolization for Hepatocellular Carcinoma with Portal Vein Tumor Thrombosis: A Propensity Score Analysis. Annals of Surgical Oncology, 2014, 21, 1825-1833.	1.5	93
96	Survival Advantage of Radiofrequency Ablation Over Transarterial Chemoembolization for Patients with Hepatocellular Carcinoma and Good Performance Status Within the Milan Criteria. Annals of Surgical Oncology, 2014, 21, 3835-3843.	1.5	19
97	Surgical Resection Is Better than Transarterial Chemoembolization for Hepatocellular Carcinoma Beyond Milan Criteria Independent of Performance Status. Journal of Gastrointestinal Surgery, 2014, 18, 1623-1631.	1.7	18
98	Decrypting Cryptogenic Hepatocellular Carcinoma: Clinical Manifestations, Prognostic Factors and Long-Term Survival by Propensity Score Model. PLoS ONE, 2014, 9, e89373.	2.5	13